3330-25-4

Usage

Synthesis Reference(s)

The Journal of Organic Chemistry, 41, p. 1648, 1976 DOI: 10.1021/jo00871a039Tetrahedron Letters, 14, p. 1719, 1973

InChI:InChI=1/C5H7ClO/c1-5(4-7)2-3-6/h2,4H,3H2,1H3/b5-2+

Upstream product

• 10523-96-3 3-methyl-3-butenyl chloride 
• 1838-94-4 isoprene epoxide 
• 503-60-6 3,3-dimethyl-allyl chloride 

Downstream Products

• 14918-80-0 3-methyl-4-oxobut-2-enyl acetate 
• 104265-19-2 ((1S,4aR,8aS)-7-Methoxy-8a-methoxymethyl-2-methyl-5,8-dioxo-1,4,4a,5,8,8a-hexahydro-naphthalen-1-yl)-acetic acid 
• 104199-10-2 ((1S,4aS,8aS)-7-Methoxy-8a-methoxymethyl-2-methyl-5,8-dioxo-1,4,4a,5,8,8a-hexahydro-naphthalen-1-yl)-acetic acid 
• 104199-08-8 ((1R,4aS,8aR)-7-Methoxy-2,8a-dimethyl-5,8-dioxo-1,4,4a,5,8,8a-hexahydro-naphthalen-1-yl)-acetic acid 
• 104199-11-3 ((1R,4aR,8aR)-7-Methoxy-2,8a-dimethyl-5,8-dioxo-1,4,4a,5,8,8a-hexahydro-naphthalen-1-yl)-acetic acid 
• 104199-05-5 (3aS,6aR,9aR,9bR)-9b-Methoxymethyl-4,7-dimethyl-3,3a,6,6a,9a,9b-hexahydro-benzo[de]chromene-2,9-dione 
• 104319-34-8 (3aS,6aR,9aS,9bR)-9b-Methoxymethyl-4,7-dimethyl-3,3a,6,6a,9a,9b-hexahydro-benzo[de]chromene-2,9-dione 
• 104199-03-3 (3aS,6aR,9aS,9bR)-4,7,9b-Trimethyl-3,3a,6,6a,9a,9b-hexahydro-benzo[de]chromene-2,9-dione 
• 104199-20-4 ((1S,4aS,8R,8aS)-8-Hydroxy-7-methoxy-8a-methoxymethyl-2-methyl-5-oxo-1,4,4a,5,8,8a-hexahydro-naphthalen-1-yl)-acetic acid 
• 104199-24-8 (3aS,6aS,9aR,9bS)-9-Methoxy-9b-methoxymethyl-4-methyl-3,3a,6,6a,9a,9b-hexahydro-benzo[de]chromene-2,7-dione 
• 104199-27-1 ((1R,4aS,8S,8aS)-8-Hydroxy-8a-methoxymethyl-2,5-dimethyl-7-oxo-1,4,4a,7,8,8a-hexahydro-naphthalen-1-yl)-acetic acid 
• 104199-22-6 (3aS,6aS,9aR,9bS)-9-Methoxy-4,9b-dimethyl-3,3a,6,6a,9a,9b-hexahydro-benzo[de]chromene-2,7-dione 
• 104293-66-5 ((1R,4aS,8S,8aS)-8-Hydroxy-2,5,8a-trimethyl-7-oxo-1,4,4a,7,8,8a-hexahydro-naphthalen-1-yl)-acetic acid 
• 104199-13-5 (2E,4Z)-6-Chloro-4-methyl-hexa-2,4-dienoic acid 

Relevant academic research and scientific papers

Efficient and stable small molecule agonist of v [gamma] 9v delta 2t cells

The invention relates to a formula (I) compound as an efficient and stable small molecule agonist of v [gamma] 9v delta 2t cells, wherein the groups are defined in the specification and the claims. The present invention also relates to pharmaceutical compositions containing the formula (I) compound and use thereof in the treatment of proliferative diseases.

Preparation method of 4-acetoxy-2-methyl-2-crotonaldehyde

The invention provides a preparation method of 4-acetoxy-2-methyl-2-crotonaldehyde. The preparation method comprises the following steps that (1) prenyl chloride is oxidized with oxygen under the effect of a catalyst into 4-chloro-2-methyl-2-crotonaldehyde; and 2) 4-chloro-2-methyl-2-crotonaldehyde and acetate are reacted to obtain 4-acetoxy-2-methyl-2-crotonaldehyde. The method is cheap and available in prenyl chloride as a starting material and short in process route as well as is economic and effective.

Preparation method of tiglic aldehyde derivative

The invention provides a preparation method of a tiglic aldehyde derivative. The preparation method comprises the following step of carrying out catalytic oxidation on an isoamylene derivative represented as the following formula (I) in the presence of a catalyst to produce the tiglic aldehyde derivative represented as the following formula (II), wherein the catalyst is a non-metal oxide, and theR in the formula (I) or the formula (II) is selected from aliphatic hydrocarbyl, aryl, aralkyl, halogens, ester groups, acyloxy, acylamino or alkoxy. The preparation method of the tiglic aldehyde derivative provided by the invention has the characteristics of few reaction step, simple process, cheap and easily available raw materials and the like.